When to start renal replacement therapy in acute kidney injury: What are we waiting for?  

作　　者：Lixia Liu Zhenjie Hu 

机构地区：[1]Department of Critical Care Medicine,The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China

出　　处：《Journal of Intensive Medicine》2024年第3期341-346,共6页重症医学（英文）

摘　　要：Acute kidney injury remains a serious condition with a high mortality risk. In the absence of any new drugs, renal replacement therapy (RRT) is the most important treatment option. Randomized controlled trials have concluded that in critically ill patients without an emergency indication for RRT, a watchful waiting strategy is safe;however, further delays in RRT did not seem to confer any benefit, rather was associated with potential harm. During this process, balancing the risks of complications due to an unnecessary intervention with the risk of not correcting a potentially life-threatening complication remains a challenge. Dynamic renal function assessment, especially dynamic assessment of renal demand-capacity matching, combined with renal biomarkers such as neutrophil gelatinase-associated lipocalin and furosemide stress test, is helpful to identify which patients and when the patients may benefit from RRT.

关 键 词：Acute kidney injury Renal replacement therapy Initiation timing Dynamic assessment Biomarkers 

分 类 号：R692[医药卫生—泌尿科学]